- Home
- BWAY vs ACIU Comparison
BWAY vs ACIU Comparison
Compare BWAY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWAY
- ACIU
- Stock Information
- Founded
- BWAY 2003
- ACIU 2003
- Country
- BWAY Israel
- ACIU Switzerland
- Employees
- BWAY N/A
- ACIU N/A
- Industry
- BWAY Medical/Dental Instruments
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- BWAY Health Care
- ACIU Health Care
- Exchange
- BWAY Nasdaq
- ACIU Nasdaq
- Market Cap
- BWAY 207.4M
- ACIU 173.7M
- IPO Year
- BWAY 2019
- ACIU 2016
- Fundamental
- Price
- BWAY $8.76
- ACIU $1.68
- Analyst Decision
- BWAY Strong Buy
- ACIU Strong Buy
- Analyst Count
- BWAY 3
- ACIU 2
- Target Price
- BWAY $13.17
- ACIU $10.00
- AVG Volume (30 Days)
- BWAY 24.0K
- ACIU 134.5K
- Earning Date
- BWAY 05-13-2025
- ACIU 04-30-2025
- Dividend Yield
- BWAY N/A
- ACIU N/A
- EPS Growth
- BWAY N/A
- ACIU N/A
- EPS
- BWAY 0.06
- ACIU N/A
- Revenue
- BWAY $41,016,000.00
- ACIU $32,014,254.00
- Revenue This Year
- BWAY $351.53
- ACIU N/A
- Revenue Next Year
- BWAY $21.84
- ACIU $676.94
- P/E Ratio
- BWAY $57.37
- ACIU N/A
- Revenue Growth
- BWAY 29.04
- ACIU 91.20
- 52 Week Low
- BWAY $5.13
- ACIU $1.43
- 52 Week High
- BWAY $11.79
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- BWAY 47.80
- ACIU 46.75
- Support Level
- BWAY $8.61
- ACIU $1.55
- Resistance Level
- BWAY $9.09
- ACIU $1.79
- Average True Range (ATR)
- BWAY 0.38
- ACIU 0.10
- MACD
- BWAY 0.05
- ACIU 0.03
- Stochastic Oscillator
- BWAY 58.73
- ACIU 66.67
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.